China SXT Pharmaceuticals, Inc. (SXTC) SEC filings

SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 1, 2026Score 4/30

$3.00+0.27 (+9.89%)

Close on Nov 13, 2026Market cap $2.87MP/E –Yield –

SEC filings

40 of China SXT Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Oct 21, 2026	Oct 21, 2026	SEC EDGAR
Current report	6-K	Oct 9, 2026	Oct 9, 2026	SEC EDGAR
Current report	6-K	Oct 8, 2026	Oct 8, 2026	SEC EDGAR
Current report	6-K	Oct 8, 2026	Oct 8, 2026	SEC EDGAR
Current report	6-K	Aug 28, 2026	Aug 28, 2026	SEC EDGAR
Current report	6-K	Jul 24, 2026	Jul 24, 2026	SEC EDGAR
Current report	6-K	Jul 6, 2026	Jul 6, 2026	SEC EDGAR
Annual report	20-F	Mar 31, 2026	Jul 1, 2026	SEC EDGAR
Current report	6-K	Jun 1, 2026	Jun 1, 2026	SEC EDGAR
Current report	6-K	May 4, 2026	May 4, 2026	SEC EDGAR
Current report	6-K	Apr 9, 2026	Apr 9, 2026	SEC EDGAR
Current report	6-K	Jan 13, 2026	Jan 13, 2026	SEC EDGAR
Current report	6-K	Sep 30, 2025	Dec 31, 2025	SEC EDGAR
Annual report	20-F	Mar 31, 2025	Jul 31, 2025	SEC EDGAR
Current report	6-K	Jul 29, 2025	Jul 29, 2025	SEC EDGAR
Current report	6-K	Jul 15, 2025	Jul 15, 2025	SEC EDGAR
Current report	6-K	Jun 16, 2025	Jun 16, 2025	SEC EDGAR
Current report	6-K	May 13, 2025	May 13, 2025	SEC EDGAR
Current report	6-K	Sep 30, 2024	Mar 28, 2025	SEC EDGAR
Current report	6-K	Mar 19, 2025	Mar 19, 2025	SEC EDGAR
Current report	6-K	Jan 27, 2025	Jan 27, 2025	SEC EDGAR
Current report	6-K	Jan 23, 2025	Jan 23, 2025	SEC EDGAR
Current report	6-K	Oct 15, 2024	Oct 15, 2024	SEC EDGAR
Annual report	20-F	Mar 31, 2024	Aug 13, 2024	SEC EDGAR
Current report	6-K	May 14, 2024	May 14, 2024	SEC EDGAR
Current report	6-K	Sep 30, 2023	Apr 5, 2024	SEC EDGAR
Annual report	20-F	Mar 31, 2023	Jul 31, 2023	SEC EDGAR
Annual report, amended	20-F/A	Mar 31, 2022	May 19, 2023	SEC EDGAR
Current report	6-K	Mar 23, 2023	Mar 23, 2023	SEC EDGAR
Current report	6-K	Feb 28, 2023	Feb 28, 2023	SEC EDGAR
Current report	6-K	Sep 30, 2022	Feb 24, 2023	SEC EDGAR
Current report	6-K	Dec 22, 2022	Dec 23, 2022	SEC EDGAR
Current report	6-K	Oct 12, 2022	Oct 12, 2022	SEC EDGAR
Current report	6-K	Sep 27, 2022	Sep 27, 2022	SEC EDGAR
Annual report	20-F	Mar 31, 2022	Jul 18, 2022	SEC EDGAR
Current report	6-K	May 13, 2022	May 13, 2022	SEC EDGAR
Current report	6-K	May 11, 2022	May 11, 2022	SEC EDGAR
Current report	6-K	Mar 24, 2022	Mar 24, 2022	SEC EDGAR
Current report	6-K	Mar 16, 2022	Mar 16, 2022	SEC EDGAR
Current report	6-K	Feb 8, 2022	Feb 9, 2022	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in China SXT Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-80 reverse split on Aug 10, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SXTC.

Compare: SXTC vs CPHI · SXTC vs XTLB · SXTC vs LGVN · SXTC vs SPRC · SXTC vs SXTP

Revenue growth-34.6% · median -11.0%

Gross margin21.9% · median 19.4%

Operating margin-625.9% · median -774.9%

Net margin-545.2% · median -729.9%

Company	Revenue	Growth
CPHI	$3.91M	-11.0%
LGVN	$1.17M	-18.9%
SXTC	$1.14M	-34.6%
SXTP	$1.11M	+73.2%
XTLB	–	–
SPRC	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: March 31
Employees: 56
Held by institutions: 0.0%
Auditor: Enrome LLP
SEC CIK: 1723980

Advertisement
300 × 250

See a number that looks wrong?